Dupilumab, commercially known as Dupixent, is a breakthrough biologic medication developed jointly by Sanofi and Regeneron Pharmaceuticals. As a leading IL-4 receptor alpha antagonist, it delivers targeted treatment for chronic inflammatory conditions including atopic dermatitis, bronchial asthma, eosinophilic esophagitis, and prurigo nodularis. Its proven clinical efficacy and expanding global regulatory approvals have established consistent, high cross-border demand, forming a structured network of global buyers spanning institutional healthcare providers, national pharmaceutical procurement bodies, wholesale pharmacy networks, and international medical supply organizations. This comprehensive guide outlines the authoritative Dupilumab global buyers list, categorizing key purchaser segments, highlighting regional market leaders, and explaining core procurement behaviors. Designed for pharmaceutical suppliers, B2B medical traders,…